BMJ Open
Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study

COVIDSurg Collaborative

ABSTRACT
Objectives Studies have demonstrated high rates of mortality in people with proximal femoral fracture and SARS-CoV-2, but there is limited published data on the factors that influence mortality for clinicians to make informed treatment decisions. This study aims to report the 30-day mortality associated with perioperative infection of patients undergoing surgery for proximal femoral fractures and to examine the factors that influence mortality in a multivariate analysis.

Setting Prospective, international, multicentre, observational cohort study.

Participants Patients undergoing any operation for a proximal femoral fracture from 1 February to 30 April 2020 and with perioperative SARS-CoV-2 infection (either 7 days prior or 30-day postoperative).

Primary outcome 30-day mortality. Multivariate modelling was performed to identify factors associated with 30-day mortality.

Results This study reports included 1063 patients from 174 hospitals in 19 countries. Overall 30-day mortality was 29.4% (313/1063). In an adjusted model, 30-day mortality was associated with male gender (OR 2.29, 95% CI 1.68 to 3.13, p<0.001), age >80 years (OR 1.60, 95% CI 1.1 to 2.31, p=0.013), preoperative diagnosis of dementia (OR 1.57, 95% CI 1.15 to 2.16, p=0.005), kidney disease (OR 1.73, 95% CI 1.18 to 2.55, p=0.005) and congestive heart failure (OR 1.62, 95% CI 1.06 to 2.48, p=0.025). Mortality at 30 days was lower in patients with a preoperative diagnosis of SARS-CoV-2 (OR 0.6, 95% CI 0.42 to 0.85), p=0.004). There was no difference in mortality in patients with an increase to delay in surgery (p=0.220) or type of anaesthetic given (p=0.787).

Conclusions Patients undergoing surgery for a proximal femoral fracture with a perioperative infection of SARS-CoV-2 have a high rate of mortality. This study would support the need for providing these patients with individualised medical and anaesthetic care, including medical optimisation before theatre. Careful preoperative counselling is needed for those with a proximal femoral fracture and SARS-CoV-2, especially those in the highest risk groups.

Trial registration number NCT04323644

BACKGROUND
The rapid worldwide spread of COVID-19, caused by the SARS-CoV-2 has had a severe effect on the elderly and frail population. A fracture of the proximal femur (neck of femur fracture) is a critical event in the elderly, frail population, with a high rate of death despite medical and surgical intervention. Since 2007, there has been a steady improvement in mortality after a proximal femoral fracture with 6.1% of patients dying within 30 days of injury in the UK in 2018. However, the emergence of COVID-19 presents a new and unquantified risk to this particularly vulnerable group.

Proximal femur fractures represent a large international burden with incidence between 43 and 920 per 100 000 population. As most fractures of the proximal femur happen as a result of trips or falls in the home, people have continued to present with this injury despite social restrictions. These patients typically have multiple comorbidities and frailty is common. Resultantly, they are particularly vulnerable to pulmonary complications. It is widely accepted that elderly patients with existing comorbidities are at higher risks of critical illness and mortality due to COVID-19, potentially due to a higher preponderance to release proinflammatory cytokines that result in severe disease.
Clinicians have been swift to respond to this pandemic with large reorganisation of service provision. In response to this, the COVIDSurg collaborative (www.globalsurg.org/covidsurg) has collected an international, large volume dataset to inform the global community of the safety of surgery in patients with perioperative SARS-CoV2 infection. The first report has demonstrated a 30-day mortality of 23.8% across patients undergoing any type of surgery. Data published so far have reported a high mortality rate in a small cohort of patients with proximal femoral fractures positive for SARS-CoV2 infection, with a maximum cohort size of 114 patients (range 10–114 patients). However, few reports have the sample size sufficient to explore the factors that influence outcome. Furthermore, large-scale data are required to explore preoperative and operative variables that influence outcomes in order to inform the clinical decision-making processes.

Aims
The primary aim of this study is to determine the mortality rate observed in patients undergoing surgery for proximal femoral fracture with perioperative SARS-CoV2 infection. Secondary, we aim to explore the patient and treatment factors associated with these outcomes.

METHODS
Setting
This is an international, multicentre cohort study including consecutive patients who underwent surgery for proximal femoral fracture from 1 February 2020 to 3 April 2020. This study is a preplanned sub-analysis of a larger, ongoing study designed to assess outcomes following all surgery for patients with perioperative SARS-CoV2 infection.

The COVIDSurg collaborative is an international, multicentre, multidisciplinary team with individual collaborators collecting data locally, which is collated centrally. The collaborative methodology, which is well described and validated, was used for this project.

Inclusion criteria
Participating hospitals included consecutive patients undergoing surgery for proximal femoral fractures that had SARS-CoV2 infection diagnosed (laboratory, clinical or radiologically) either 7 days preoperatively or up to 30 days postoperatively. For those diagnosed preoperatively, this represents the timeframe where the majority of patients still active disease. For those patients who underwent multiple procedures, the procedure closest to the time of confirmation of SARS-CoV2 infection was defined as the index procedure.

Patients received laboratory confirmation of SARS-CoV2 using quantitative reverse transcription Polymerase Chain Reaction (qRT-PCR). As qRT-PCR is not available in all participating hospitals, patients were included if their diagnosis was made by clinical or radiological findings. Clinical diagnosis was made in patients presenting with symptoms and a clinical pattern of COVID-19. These included cough, fever and/or myalgia. Radiological diagnosis was made through CT scanning of the thorax according to local protocols. All patients who were included solely on clinical or radiological suspicion but had a subsequent negative qRT-PCR test were excluded from the database by individual collaborators.

Diagnosis
This study includes all patients identified as having an operation for a proximal femoral fracture. The diagnosis was established pragmatically by the local site teams according to their assessment of the fracture. The reported data were screened by a central dedicated data cleaning team, with only confirmed proximal femoral fractures included in the cohort.

Patient identification
Researchers at participating centres screened consecutive patients undergoing surgery to ensure all patients were identified. The study was initiated in some countries after their peak of infection, and therefore retrospective identification and data collection was permitted, as long as the data collection was consecutive at that site.

To reduce selection bias, a variety of written materials were distributed to site leads to highlight possible methods of identifying patients ensuring all eligible patients were included. Investigators were invited to social media groups and online teleconferences to troubleshoot recruitment issues, share learning and ensure consistent recruitment into the wider cohort.

Outcome measures
The primary outcome measure was 30-day all-cause mortality, with the day of surgery defined as day zero. The secondary outcome measure was rate of pulmonary complications, which is a composite outcome defined previously from the Prevention of Respiratory Insufficiency after Surgical Management randomised controlled trial.

Pulmonary complications were defined as pneumonia, acute respiratory distress syndrome and/or unexpected postoperative ventilation; these have been identified as the most frequent COVID-19 related pulmonary complications in medical patients. Unexpected postoperative ventilation was defined as either: (1) any episode of non-invasive ventilation, invasive ventilation or extracorporeal membrane oxygenation after initial extubation following surgery or (2) unexpected failure to extubate following surgery.

Data collection and quality assurance
Data were collected online using the Research Electronic Data Capture web application. Demographic variables recorded consisted of age, sex and American Society of Anesthesiologists (ASA) physical status classification. Age was collected as a categorical variable by decades of age. ASA at the time of surgery was dichotomised to (1)
grades 1–2 and (2) grades 3–5 for the purpose of analysis, time to surgery to (1) under 24 hours, (2) 24–48 hours and (3) over 48 hours and surgery to (1) hemiarthroplasty, (2) total hip replacement, (3) dynamic hip screw, (4) cannulated screws and (5) intramedullary nail. The timing of SARS-CoV-2 diagnosis was recorded as either preoperative or postoperative.

Before data were entered into analysis, site principle investigators were required to confirm all consecutive eligible cases had been completed and uploaded. Where diagnosis was unclear, authors were contacted for clarification.

Statistical analysis
The study was reported according to Strengthening the Reporting of Observational Studies in Epidemiology guidelines. Proportions are expressed with 95% CIs, and the mean and 95% CIs were used where data were assumed to be approximately normally distributed. Fisher’s exact test was used for categorical data. Non-parametric data was summarised with the median and IQRs. Statistical significance was assessed at the 5% level.

The risk of death at 30 days was chosen as the primary outcome for the study. Mixed-effects logistic regression analysis was used to assess the strength and significance of associations between a number of explanatory variables and death within 30 days. Random effects were included in the mixed-effects model to account for the hierarchical structure of the data (individual hospital effects are naturally nested within country effects), and fixed effects were included to adjust for a range of preoperative variables that may influence mortality in this population and relevant factors related to the injury or treatment (eg, type of operation, time from admission to operation and type of anaesthetic). An additional analysis of the same factors was undertaken using the same model structure for the secondary outcome of pulmonary complications. This was an exploratory analysis with the significance level set at 5%, with no specific adjustments made for model testing. All analyses were implemented in R (R Core Team 2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org).

RESULTS
Population
This study returned 30-day follow-up for 1063 patients with proximal femoral fractures. Data were collected in 174 hospitals from 19 countries (online supplemental table 1). Of these, 65.5% were female (696/1063). A percentage of 7.8% (83/1063) patients were <70 years old, 17.8% (189/1063) were between 70 and 79 years, 47.7% (507/1063) were between 80 and 89 years old and 26.7% (284/1063) were 90+ years old.

Mortality
Overall 30-day mortality was 29.4% (313/1063). With each decade of age, mortality significantly increased, being highest in those patients >90 years old (38.7% (110/284), p=0.001).

In an adjusted model (figure 1), 30-day mortality was associated with male gender (OR 2.29, 95% CI 1.68 to 3.13, p<0.001), age >80 years (OR 1.60, 95% CI 1.1 to 2.31, p=0.013), diagnosis of dementia (OR 1.57, 95% CI 1.15 to 2.16, p=0.005), chronic kidney disease (OR 1.73, 95% CI 1.18 to 2.55, p=0.005) and congestive heart failure (OR 1.62, 95% CI 1.06 to 2.48, p=0.025). Thirty-day mortality was lower in patients with a preoperative diagnosis of SARS-CoV-2 (OR 0.60, 95% CI 0.42 to 0.85, p=0.004). Non-adjusted values are presented in online supplemental table 2.

Pulmonary complications
In an adjusted model (figure 2), respiratory complications were associated with male gender (OR 1.7, 95% CI 1.27 to 2.28, p=0.001), diagnosis of dementia (OR 1.34, 95% CI 1.01 to 1.79, p=0.044) and congestive heart failure (OR 1.76, 95% CI 1.17 to 2.63, p=0.006). The presence of chronic obstructive pulmonary disorder showed no significant association (OR 1.42, 95% CI 0.96 to 2.09, p=0.076).

Diagnosis
The majority of diagnosis of SARS-CoV-2 was made via PCR swab testing 93.3% (992/1063) (online supplemental tables 1 and 3), and there was no difference in mortality between those diagnosed clinically (p=0.668). The majority of patients 69% (733/1063) were diagnoses postoperatively.

Preoperative variables
Preoperative symptoms (online supplemental table 4), including breathlessness, cough and fever (>38°C) were not significantly different in patients who were alive or dead at 30 days postoperatively. On examination of preoperative observations, a high respiratory rate was predictive of mortality (OR 1.73 95% CI 1.18 to 2.55, p=0.025) (figure 1). However, there was no significant difference in patient’s heart rate, systolic or diastolic blood pressure (online supplemental table 5 and figure 1) between those who were alive or dead at 30 days.

Those patients with ASA grade 3–5 had a significantly higher mortality of 31.4% (281/899) versus ASA of 1–2 of 18.5% (28/151), p=0.001.

Procedures
The operations were carried out under a general anaesthetic in 49.6% (527/1063) of patients (online supplemental table 6). A percentage of 67.2 (714/1063) of patients did not require any preoperative oxygen therapy. In this cohort, 31.8% (338/1063) of patients had their preoperative or postoperative.
operation within 24 hours of presentation to hospital, 21.1% (224/1063) had their operation between 24 and 47 hours and 19.2% (205/1063) of patients had their operation after 48 hours of presentation to hospital.

In this cohort, 45.1% (479/1063) of patients underwent hemiarthroplasty with a further 4.2% undergoing total hip replacement (45/1063). For patients who underwent fixation, 26% (276/1063) underwent dynamic hip screw fixation, 22.9% (243/1063) patients underwent intramedullary fixation, 0.5% (5/1063) underwent cannulated screw fixation, while a further 1.4% (15/1053) underwent internal fixation.

There was no difference in mortality between patients undergoing general and regional anaesthesia (29.9% (157/527) vs 29.0% (152/524), p=0.787). However, there was an increased mortality in those patients requiring preoperative oxygen therapy (34.3% (115/336) vs 27.2% (194/714), p=0.031).

There was no significant difference in mortality for patients with delayed operation. The highest mortality was for patients operated between 24 and 47 hours of admission (34.4% (77/224)) but was not significantly higher than those operated after 48 hours (p=0.220).
Mortality was highest in March (33.7%, 159/474) compared with April (27.0%, 150/558) and February (11.5%, 3/26), p=0.007 (online supplemental table 1).

**DISCUSSION**

The 30-day mortality rate for patients with a perioperative diagnosis of SARS-CoV-2 infection undergoing surgery for proximal femoral fracture is substantial. An overall rate of 29.4% compares with the reported 30-day mortality in the literature for proximal femoral fractures ranging between 3.5% and 6.8%. This rate is higher than found at the 1-year time point.35 Furthermore, elderly patients and those with medical comorbidities such as dementia, chronic kidney disease and congestive heart failure were associated with higher risk of 30-day mortality. Notably, patients with a preoperative diagnosis of SARS-CoV-2 infection had lower rates of 30-day mortality, likely reflecting early recognition and closer management of these patients. Findings from this study will be useful in guiding clinicians to identify high-risk patients that may warrant closer medical and surgical input during the COVID-19 pandemic.

Considering this high mortality, it is critical that patients who present without a diagnosis SARS-CoV-2 with proximal femoral fractures are protected from contracting the infection preoperatively. A study by Kayani et al37 has suggested that half of infections in patients with proximal femoral fractures occur in hospital, as denoted by having negative preoperative samples. Similarly, a study by Hall et al34 has suggested nearly half of cases were due to nosocomial transmission. Within this study, 733 (69%) of infections were diagnosed postoperatively. This may infer that infections have been transferred in hospital, although due to incubation period of the virus, it is hard to know the proportion that contracted the virus prior to presentation or in hospital.7 35 Higher mortality was observed in people who had a postoperative diagnosis, which emphasises the critical importance of avoiding in-hospital transmission. Hospitals should consider implementation of careful infection control processes to minimise and prevent transmission of SARS-CoV-2 infection. Within the elective setting, the creation of COVID-19 free surgical pathways for elective patients has been shown to reduce infection and subsequent mortality36–38 and while only some of the principles are transferrable to the emergency setting, it demonstrates the value of meticulous infection control processes throughout the hospital stay. Furthermore, patients should be reinforced of methods to reduce risk of transmission in the community after discharge, including (but not limited to) social distancing, isolation and hygiene.

For those patients presenting with SARS-CoV-2 (either existing diagnosis or clinical findings suggestive of) and a proximal femoral fracture, it is important for data to be used as part of the informed consent process. In patients with multiple high-risk factors such as those who are more elderly, have respiratory and cardiac comorbidities, non-operative management may be considered following an appropriate discussion with the patient and/or their family. Every year in the UK, 2.5% of hip fractures are treated non-operatively.39 A study performed before the pandemic reported that the mortality within 30 days for conservatively treated patients was 31.3%.40 We do not know the mortality from non-operative management during the pandemic for patients with SARS-CoV-2, but the particularly high mortality associated with surgery in high-risk groups may change the balance of benefit and harm towards conservative treatment, and this should be considered.

The 30-day mortality of 29.4% identified within this study is comparable with published literature in the UK (range from 16.3% to 35.6%),15–17 19 34 41 Italy (18.75%),14 Spain (30.4%)13 and the USA (range from 35.3% to 56%).18 20 From a study within the UK, the authors also found a correlation between male sex and increased mortality (OR 2.69), which is similar to that demonstrated in this study (OR 2.29).16 39 Additionally, another UK study reported having more than three comorbidities as a risk factor for mortality.17 This study has specifically delineated a diagnosis of dementia, chronic kidney disease and congestive heart failure as being independent risk factors for mortality. In a study from USA, the authors found those patients who died were older with multiple comorbidities, and this was reflected in statistically significantly higher ASA scores in comparison with their negative counterparts.20

This study found that there was no significant increase in mortality with delay to surgery. Current guidelines suggest early surgery should be undertaken,42 and this is associated with lower mortality.43 This would suggest that those patients at the highest risk of mortality can have medical optimisation, if appropriate, and will not result in a higher mortality from SARS-CoV-2 infection. This includes correction of concurrent medical issues often found in this population, examples of which include correction of acute renal failure, electrolyte disturbances and/or anticoagulation related issues. With regards to recovery from SARS-CoV-2 infection, it is important to consider that an increased risk of mortality for those undergoing surgery persists until 7 weeks after diagnosis.44 This risk reduces gradually after 2 weeks after diagnosis and should be considered.

Similarly, previous studies have found a higher rate of mortality in patients undergoing general versus regional anaesthesia for proximal femoral fractures.45 46 This study reports no difference between general and regional anaesthetic (29.9% vs 29.0%, p=0.787). While this was not the primary outcome of this study, this suggests that a positive test for SARS-CoV-2 should not have a large influence on anaesthetic decisions. This should be interpreted with caution in the light of this being an exploratory study. Out of all clinical features, respiratory rate at presentation was associated with higher mortality. Clinicians should focus on this as an important finding when counselling patients of their perioperative mortality.
This study has also found an increased mortality during the month of March 2020. This corresponds to the peak of caseload of infections internationally.47 48 Increased circulation of SARS-CoV-2 within countries has shown to increase mortality through higher viral loads.49 50 This study validates that surgical patients are particularly susceptible during surge of cases.

This is a large, varied cohort of patients undergoing surgery for a proximal femoral fractures with SARS-CoV-2 infection diagnosed perioperatively. This study was conducted in multiple centres, internationally, allowing it to be generalisable across populations in other countries.

**Strength and Limitations**

This study was conducted in hospitals in the early to midphase of the pandemic where routine testing was not available in all participating centres. As such, to be pragmatic, patients were included if a clinical diagnosis was made by the treating physician. Protocols were not standardised for clinical diagnosis and were left the senior treating physician. Laboratory diagnosis was made by qRT-PCR, from which false-negative results may have excluded patients from analysis. Indeed, the sensitivity of qRT-PCR testing for has shown to be as low as 32% for throat swabs.50 However, in patients with negative results and high clinical suspicion of SARS-CoV-2 infection, multiple samples are often taken, including broncho-alveolar lavage. Thus, the number of patients excluded is expected to be low. While this study reports a higher mortality from postoperative diagnosis of SARS-CoV-2 infection, it is unclear whether the infection was contracted preoperatively or not, as has been discussed previously.

This study does not have a control arm, assessing contemporaneous patients with undergoing an operation for proximal femoral fractures without SARS-CoV-2 infection during the height of the pandemic. However, comparison with high-prevalence pandemic data strongly suggests a substantial increase in mortality. Patients and those who care for them should consider this carefully when making decisions in this common and challenging clinical scenario.

**CONCLUSION**

Patients undergoing surgery for a proximal femoral fracture with a peri-operative infection of SARS-CoV-2 have a high rate of mortality. The study would support the approach of providing these patients with individualised medical and anaesthetic care, including medical optimisation before theatre. It is imperative to prevent transmission of COVID-19 in the hospital setting. Careful preoperative counselling is needed for those with a proximal femoral fracture and SARS-CoV-2, especially those in the highest risk groups.

**Acknowledgements**

Xiao Liu and Alistair Denniston, Royal College of Surgeons of England COVID-19 Research Group.

**Collaborators**

COVIDSurg authorship list: Writing group: C Khatri, A E Ward, D Nepogodiev, I Ahmed, D Chaudhry, F Dhaif, B Bankhead-Kendall, H Kaafarani, C Bretherton, A Mahmood, L Marais, N Parsons, A Bhangoo, A Metcalfe (senior author & overall guarantor). Statistical analysis: N Parsons (lead statistician), C Khatri. Operations Committee: K Siaw-Acheampong, D Chaudhry, B E Dawson, J P Evans, J C Glasby, R R Gujri, E Heritage, C S Jones, S Kamarajah, C Khatri, M J Keatley, S Lawday, E Li, S C Mickay, D Npogodige, G Pelling, A Tiwari, J F F Simoes (chair). Collaborators (*asterisk indicates principle investigator): J M Trout, L M Vidy, D Vimalachandran, N Wright, EuroSurg, European Society of Coloproctology, GlobalSurg, GlobalPeedSurg, IT Surg, PTSurg, Spain Surg, E-ECO, J F F Simoes (chair). Collaborators (*asterisk indicates principle investigator): M JC, Kulkarni, R Sharma, N Nankivel, P Tirotta, F Parente, A Breik, O Kisek, A Cato LDD, Saeed, S Banga A, Griffiths E, Pathanaki AM, Ford S, Desai A, Almond M, Kamal M (Queen Elizabeth Hospital Birmingham, United Kingdom); Chobara A, Lecolle K, Truant S, El Amrani M, Zarib, P Pruvot FR, Mathieu D, Surmey E, Mattai L, Marin H (CHU Lille, France); Dudev J, Singhal T, El-Hasani (Princess Royal Hospital NHS Trust, United Kingdom); Nehra D, Watters A, Cuscieri, J Davidson GH (Harborview Medical Center, United States); Ho M, Wade RG, Johnstone J, Bourke G, Brunelli A, Eldahi H, Otify M, Pompilii C, Burke JR, Bagouri E, Chowdhury M, Abual-Rub, Z, Kaufmann A, Munir S, Lo T, Young A, Kawal M, Wall J, Peckham-Colyn (The Leeds Teaching Hospitals NHS Trust, United Kingdom); Wrigley SC, Elektor E, Stavroulakis D, Di Chiara, F Walkork, Kureishi A, Lami M, Srahavan S, Mastoridis S, Shah K, Chidambaram S, Smillie R, Shaw A, Bandypoyadhyay S, Cerni C, Bretherton C, Jyaretna D, Garau M, Pupa R, Duck E, Brown S, Jelley C, Tucker SC, Bond-Smith G, Griffin XL, Tebala GD, Neal N, Vatish M, Notton TM, Ghattaura H, Maher M, Fu H, Risk OB, Soleymani majd H, Sinha S, Shankar S, Aggarwal A, Kharkar A, Lakhooh K, Verberne C, Mastoridis S (Oxford University NHS Foundation Trust, United Kingdom); Senent-Boza A, Sánchez-Arteaga A, Benítez-Linero I, Manresa-Manresa F, Talón-Aguilar L, Melero-Cortés L, Fernández-Marin MR, Durán-Muñoz-Cruzado VM, Ramallo-Solis I, Beltrán-Miranda P, Parera-Guíor F, Antón-Éguira BT (Hospital Universitario Virgen Del Rocío, Spain); Dawson AC*, Drake A (GFos Hospital, Austria); Olwa Mompean F, Gomez-Rosado J*, Reguera-Rosal J, Valdez Hernandez J, Capitan Morales-Lerol E, Lopez MT, (Hospital Universitario Virgen Macarena, Spain); Patel M, Shabana A, Alabnuki A*, Usman O (Brighton and Sussex NHS Trust, Princess Royal Hospital, United Kingdom); Mann A, Beamish AJ, Price C, Bosanquet D*, Magowan D, Solari F, Williams G, Nasa H, Smith L (Royal Gwent Hospital, United Kingdom); Elliott L, Mccabe G, Holroyd D*, Jamieson NB (Glasgow Royal Infirmary, United Kingdom); Mariani NM*, Nicastro V (A Stato Paolo E Carlo, Italy); Li Z*, Parkins K, Spencer N, Harrnes R, Egan RJ, Motter D, Jenvey C, Mahoney R, Fine N, Minto T, Henry A, (Musgrove Hospital, United Kingdom); Gill C, Dunne N, Surname C, Goodbole C, Carlos W, Tewari N*, Jeevan D, Naredia P, Khajuria A, Connolly H, Robertson S, Sweeney C, Di Taranto G, Shanbhag S, Dickson K, McEvoy K, Skillman J, Sait M, Al-omishy H, Baig M, Heer B (University Hospitals Coventry and Warwickshire NHS Trust, United Kingdom); Cruickshank R*, Sheel ARG, Sundhu M, Santini AJA, Fathelhab CMSAT, Hussein KMA, Nunes OM, Jones RP, Shahzad K, Haq I, Baig MMAS, Hughes JL, Kakkayatam A, Rajput K, Misra N, Shah SB, Clynch AL, Georgopoulos N, Sharpes HM, Aampa AA, Nzenwa IC, Sud A (Antirenova Hospital, Liverpool University Hospitals NHS Foundation Trust, United Kingdom); Podolsky D*, Coleman NL, Callahan MP (NewYork-Presbyterian / Columbia University Medical Center, United States); Dunstan MT*, Beak P, Georgianni I* (Kingston Hospital NHS Foundation Trust, United Kingdom); Ebrahim A, Alwadyia A, Goyal A*, Phillips A, Bhalla A*, Demetriou C, Grimeley E, Theophiliou E, Ogden E, Malcolm FL, Davies-Jones G, Ng JCK, Mirza M, Hassan M, Elmaleh N, Dalipa Y, Williams P, Bateman A*, Chia Z (Royal Dental Hospital, United Kingdom); A’Court J, Konarski A, Faulkner G* (Royal Bolton Hospital, United Kingdom); Talwar R*, Patel K, Askari A, Jambulingam P S, Shaw S, Malty A, Hatzantonis C, Sagar J, Kudchadkar S, Ciocchi N, Chan CH (Luton and Dunstable University Hospital, United Kingdom); Eberbach H*, Bayer J*, Erdle B, Sandkamp R (Medical Center – Albert-Ludwigs-University of Freiburg, Faculty of Medicine, Germany); Kaafarani H*, Breun K, Bankhead-Kendall D, Aler O, Maslari H, Velmauros G, Maurer LR, El Mohel M, Gaitanidis A, Naar L, Christensen MA, Kapeon C, Langeveld K, El Hechi M, Mokhtari A (Massachusetts General Hospital, United States); Main B, Maccabe T, Newton C*, Blencowe NS, Fulop DD, Bhovjani D, Baquadano M, Caputo M*, Rapetto F, Flannery, O, Hassan A (University Hospitals of
COVID-19 infection: the contribution of “inflame-aging”. *Inflammation Research* 2020;69:825–39.
10. Chang Liang Z, Wang W, Murphy D, et al. Novel coronavirus and orthopaedic surgery: early experiences from Singapore. *J Bone Joint Surg Am* 2020;102:e749–50.
11. Thornton J. Clinicians are leading service reconfiguration to cope with covid-19. *BJM* 2020;369: m1444.
12. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. *Lancet* 2020;396:27–38.
13. Muñoz Vives JM, Jornet-Gibert M, Cámara-Cabrera J, et al. Mortality rates of patients with proximal femoral fracture in a worldwide pandemic: preliminary results of the Spanish HIP-COVID observational study. *J Bone Joint Surg Am* 2020;102:e69.
14. Catellani F, Coscione A, D'Ambrosi R, et al. Treatment of proximal femoral fracture fragility fractures in patients with COVID-19 during the SARS-CoV-2 outbreak in northern Italy. *J Bone Joint Surg Am* 2020;102:e58.
15. Mamarouli G, Oduoza U, Chekuri R, et al. Mortality in patients with proximal femoral fracture during the COVID-19 pandemic: a U.K. hospital’s experience. *JB JS Open Access* 2020;5. doi:10.2106/JBJS.OA.20.00086. [Epub ahead of print: 23 11 2020].
16. Rasidovic D, Ahmed I, Thomas C, et al. Impact of COVID-19 on clinical outcomes for patients with fractured hip: a multicentre observational cohort study. *BJ J Orthop Trauma* 2020;34:395–402.
17. Kayani B, Onchoie E, Patil V, et al. The effects of COVID-19 on perioperative morbidity and mortality in patients with hip fractures. *Bone Joint J* 2020;102-B:1136–45.
18. Egoł KA, Konda SR, Bird ML, et al. Increased mortality and major complications in hip fracture care during the COVID-19 pandemic: a new York City perspective. *J Orthopa Trauma* 2020;34:395–402.
19. Thakrar A, Chui K, Kapoor A, et al. Thirty-Day mortality rate of patients with hip fractures during the COVID-19 pandemic: a single centre prospective study in the United Kingdom. *J Orthopa Trauma* 2020;34:e325–9.
20. LeBrun DG, Konnaris MA, Ghahramani GC, et al. Hip fracture outcomes during the COVID-19 pandemic: early results from New York. *J Orthopa Trauma* 2020;34:403–10.
21. Bhangoo A, Kolas AG, Pinkey T, et al. Surgical research Collaborators in the United Kingdom. *Lancet* 2020;396:1091–2.
22. Cevik M, Kuppalli K, Kindrachuk J, et al. Virology, transmission, and pathogenesis of SARS-CoV-2. *BJM* 2020;371:m3862.
23. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054–62.
24. Abbott TEF, Fowler AJ, Pelosi P, et al. A systematic review and consensus definitions for standardised end-points in perioperative medicine: pulmonary complications. *Br J Anaesth* 2018;120:1066–70.
25. Pearse RM, Abbott TE, Haslop R, et al. The prevention of respiratory insufficiency after surgical management (PriSM) trial. Report of the protocol for a pragmatic randomized controlled trial of CPAP to prevent respiratory complications and improve survival following major abdominal surgery. *Minerva Anestesiol* 2017;83:175–82.
26. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing research registration and data management and analysis tools. *J Biomed Inform* 2009;42:377–81.
27. Gharabeh A, Kopikar S, J. Bonilla-Escobar, F. Strengthening the reporting of observational studies in epidemiology (STROBE) in the International Journal of Medical students. *International Journal of Medical Students* 2014;2:36–7.
28. Blanco JF, da Casac C, Estaca-Hernández C, et al. 30-Day mortality after hip fracture surgery: influence of postoperative factors. *PLoS One* 2021;16:e0246963.
29. Carretta E, Bochicchio V, Rucci P, et al. Hip fracture: effectiveness of early surgery to prevent 30-day mortality. *Int Orthop* 2020;44:219–24.
30. Giannoudis P, Calori GM, Simou-Nicol, et al. Similar mortality rates in hip fracture patients over the past 31 years: a systematic review of RCTs. *Acta Orthop* 2014;85:54–9.
34 Hall AJ, Clement ND, MacLullich AM, et al. IMPACT-Scot 2 report on COVID-19 in hip fracture patients: a nationwide study of mortality, risk factors for community and hospital acquired COVID-19, and suggested care pathways. The Bone & Joint Journal 2021;103:1–10.
35 Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med 2020;8:506–17.
36 COVIDSurg Collaborative. Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic. Br J Surg 2021;108:88–96.
37 Chui K, Thakrar A, Shankar S. Evaluating the efficacy of a two-site ('COVID-19' and 'COVID-19-free') trauma and orthopaedic service for the management of hip fractures during the COVID-19 pandemic in the UK. Bone Jt Open 2020;1:190–7.
38 Glasbey JC, Nepogodiev D, Simes JFF, et al. Elective cancer surgery in COVID-19-Free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study. J Clin Oncol 2021;103-B:782–7.
39 National Hip Fracture Database. National hip fracture report, 2020. Available: https://www.nhfd.co.uk/20/NHFDcharts.nsf/vwcharts/Surgery/topendocument
40 Moulton LS, Green NL, Sudahar T, et al. Outcome after conservatively managed intracapsular fractures of the femoral neck. Ann R Coll Surg Engl 2015;97:279–82.
41 Mahmood A, Rashid F, Limb R, et al. Coronavirus infection in hip fractures (CHIP) study. Bone Joint J 2021;103-B:782–7.
42 Hoffenberg R. Fractured neck of femur, prevention and management. summary and recommendations of a report of the Royal College of physicians. J R Coll Physicians Lond 1989;23:8–14.
43 Rogers FB, Shackford SR, Keller MS. Early fixation reduces morbidity and mortality in elderly patients with hip fractures from low-impact falls. J Trauma 1995;39:261–5.
44 GlobalSurg Collaborative. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia 2021;76:748–58.
45 Ahn EJ, Kim HJ, Kim KW, et al. Comparison of general anaesthesia and regional anaesthesia in terms of mortality and complications in elderly patients with hip fracture: a nationwide population-based study. BMJ Open 2019;9:e029245.
46 Van Waesbergh J, Stevanovic A, Rossaint R, et al. General vs. neuraxial anaesthesia in hip fracture patients: a systematic review and meta-analysis. BMC Anesthesiol 2017;17:87.
47 Ferguson N, Laydon D, Nedjati-Gilani G, et al. Report 9: impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. Imperial College London 2020;10:491–7.
48 University, J.H. Coronavirus resource centre, 2021. Available: https://coronavirus.jhu.edu/data
49 Fajnzylber J, Regan J, Coxen K, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun 2020;11:1–9.
50 Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020;323:1843–4.
51 COVIDSurg Collaborative. COVIDSurg protocol 2020 https://globalsurg.org/covidsurgcohortstudy/